Aripiprazole (Abilify, Abilify Maintena, Aristada, Abilify Asimtufii, Abilify MyCite)
Aripiprazole is a widely used atypical antipsychotic with D2 partial agonist activity. Its 2026 role spans schizophrenia, bipolar I disorder, MDD augmentation, irritability associated with autism spectrum disorder, and Tourette syndrome, with multiple long-acting injectable formulations including the every-2-month Abilify Asimtufii (2023).
- Mechanism of action
- Dopamine D2 and serotonin 5-HT1A partial agonist and 5-HT2A antagonist. The resulting 'dopamine system stabilizer' profile carries lower rates of hyperprolactinemia and metabolic disturbance than many atypicals.
- Administration route
- Oral; long-acting injectable formulations (Abilify Maintena monthly, Aristada monthly/6-weekly/2-monthly, Abilify Asimtufii every 2 months).
FDA-approved indications (2026)
Schizophrenia
Adults and adolescents ≥13 years.
Bipolar I disorder
Acute manic/mixed episodes and maintenance; pediatrics ≥10 years.
MDD adjunctive
Adjunct to antidepressants.
Autism spectrum disorder — irritability
Children ages 6–17.
Tourette syndrome
Children ages 6–18.
Dosing: adult, renal, and hepatic
| Population | Dose |
|---|---|
| Schizophrenia (adults) | 10–15 mg PO daily; max 30 mg/day. |
| Bipolar I mania (adults) | 15 mg PO daily; titrate to 30 mg/day. |
| MDD adjunctive | Start 2–5 mg daily; titrate to 5–10 mg/day (max 15). |
| LAI — Abilify Maintena | 400 mg IM monthly (300 mg if CYP2D6 PM or concomitant strong inhibitors). |
| LAI — Abilify Asimtufii | 960 mg IM every 2 months after oral tolerability confirmed. |
| Renal / hepatic impairment | No dose adjustment. |
| CYP2D6 poor metabolizers | Halve the usual dose. |
Contraindications and boxed warnings
Contraindications
- Serious hypersensitivity to aripiprazole.
Boxed warnings
- Increased mortality in elderly patients with dementia-related psychosis.
- Suicidal thoughts and behaviors in children, adolescents, and young adults with MDD and other psychiatric disorders.
2026 guideline and pivotal trial position
APA 2020 schizophrenia guideline and 2024 update position aripiprazole as a reasonable first-line atypical, especially where metabolic burden is a concern. CANMAT-ISBD 2018 and 2023 bipolar updates list aripiprazole as first-line for acute mania and maintenance. 2026 practice increasingly leverages LAIs to address adherence, with Abilify Asimtufii's every-two-months dosing reducing injection burden.
CATIE (aripiprazole arm — later analyses)
Comparable efficacy with more favorable metabolic profile vs some atypicals.
Abilify Maintena registration program
Noninferiority vs oral aripiprazole; reduced relapse vs placebo in schizophrenia.
Abilify Asimtufii program (2023)
Noninferior PK and relapse outcomes vs monthly Maintena; supports q2-monthly dosing.
Cross-system reasoning
Aripiprazole's activation profile can trigger akathisia that presents as agitation or worsening anxiety — an important psychiatry-primary care coordination point. Impulse-control side effects (pathological gambling, hypersexuality) are well-described and require explicit counseling. CYP2D6 interactions affect dosing when patients are on strong inhibitors (paroxetine, fluoxetine). Cardiometabolic monitoring remains standard despite the drug's comparatively benign profile.
Key references
Related clinical reading
Explore Aripiprazole in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
This reference is for US-licensed physicians and is not a substitute for the full FDA prescribing information. Dosing in special populations, drug interactions, and emerging safety information should be verified against the current manufacturer label and society guidelines before prescribing.